Porton Fine Chemicals Ltd - Asset Resilience Ratio

Latest as of September 2025: 6.85%

Porton Fine Chemicals Ltd (300363) has an Asset Resilience Ratio of 6.85% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300363 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥588.05 Million
≈ $86.05 Million USD Cash + Short-term Investments

Total Assets

CN¥8.58 Billion
≈ $1.26 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2020)

This chart shows how Porton Fine Chemicals Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Porton Fine Chemicals Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Porton Fine Chemicals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Porton Fine Chemicals Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥588.05 Million 6.85%
Total Liquid Assets CN¥588.05 Million 6.85%

Asset Resilience Insights

  • Limited Liquidity: Porton Fine Chemicals Ltd maintains only 6.85% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Porton Fine Chemicals Ltd Industry Peers by Asset Resilience Ratio

Compare Porton Fine Chemicals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
Drug Manufacturers - Specialty & Generic 10.89%
KPC Pharmaceuticals Inc
SHG:600422
Drug Manufacturers - Specialty & Generic 16.37%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
Drug Manufacturers - Specialty & Generic 3.51%
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
Drug Manufacturers - Specialty & Generic 5.72%

Annual Asset Resilience Ratio for Porton Fine Chemicals Ltd (2017–2020)

The table below shows the annual Asset Resilience Ratio data for Porton Fine Chemicals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-12-31 0.09% CN¥4.14 Million
≈ $605.43K
CN¥4.50 Billion
≈ $658.04 Million
+0.09pp
2019-12-31 0.01% CN¥224.20K
≈ $32.81K
CN¥3.96 Billion
≈ $578.81 Million
-13.03pp
2018-12-31 13.03% CN¥570.21 Million
≈ $83.44 Million
CN¥4.37 Billion
≈ $640.12 Million
+13.00pp
2017-12-31 0.04% CN¥1.06 Million
≈ $155.70K
CN¥2.85 Billion
≈ $416.76 Million
--
pp = percentage points

About Porton Fine Chemicals Ltd

SHE:300363 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.63 Billion
CN¥11.16 Billion CNY
Market Cap Rank
#7096 Global
#1692 in China
Share Price
CN¥20.53
Change (1 day)
-1.91%
52-Week Range
CN¥14.88 - CN¥29.41
All Time High
CN¥97.10
About

Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more